List of Excipients in Branded Drug YCANTH

YCANTH Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

YCANTH is a prescription topical solution containing 0.7% cantharidin for molluscum contagiosum in adults and children aged 2 years and older. Its commercial differentiation depends on more than cantharidin: the solvent system, viscosity control, applicator, single-use packaging, controlled exposure time, and office-based administration create the product’s practical value.

The main commercial opportunity is to develop safer, more convenient, and more scalable cantharidin delivery systems without compromising lesion penetration or the visible blistering response required for efficacy. The primary competitive risks are formulation workarounds, 505(b)(2) products, compounded cantharidin preparations, and future products that reduce office visits.

What is YCANTH and how does its formulation work?

YCANTH is a topical cantharidin solution supplied in single-use applicators. Healthcare professionals apply it directly to molluscum lesions, leave it in place, and wash it off after 24 hours or sooner if severe blistering or adverse reactions occur. Treatment may be repeated every three weeks for up to four applications (FDA, 2023a).

The approved formulation contains:

Component	Function in product strategy
Cantharidin 0.7%	Active vesicant that produces intraepidermal blistering and lesion clearance
Volatile organic solvents	Dissolve cantharidin, wet the lesion surface, and promote drying after application
Hydroxypropyl cellulose or comparable cellulose-based rheology control	Helps keep the formulation at the application site and controls spreading
Castor oil or other emollient component	Supports spreadability and may reduce excessive drying
Camphor or related sensory excipient, where present in the approved composition	Contributes to sensory profile and may affect local evaporation and tolerability
Single-use applicator	Limits cross-contamination, controls dose handling, and supports in-office administration

The precise inactive-ingredient list and quantitative composition are controlled by the FDA-approved labeling and Chemistry, Manufacturing, and Controls package. The product’s commercial design is closely tied to the applicator rather than to a conventional multidose tube.

What excipients protect YCANTH’s performance?

Solvent selection

Cantharidin has limited water solubility. A nonaqueous solvent system is therefore central to product performance. The solvent must maintain cantharidin in solution during storage, enable uniform delivery to small lesions, and evaporate at a predictable rate after application.

A solvent system that evaporates too quickly may produce uneven dosing and crystallization. A system that evaporates too slowly can increase spreading beyond the lesion and prolong patient exposure. Pediatric use makes control of volatility, odor, flammability, and skin irritation commercially important.

The strongest formulation opportunity is a solvent blend that preserves cantharidin solubility while reducing odor and sting. Such a change could support a differentiated product, but it would require comparative data demonstrating equivalent exposure and clinical effect.

Rheology and lesion-site retention

Molluscum lesions are small, raised, and often numerous. The formulation must wet each lesion without running onto surrounding skin. A cellulose-based thickener can provide modest viscosity without making the product difficult to apply through a narrow applicator.

Rheology is a potential source of intellectual-property differentiation. A formulation with controlled shear-thinning behavior could remain viscous at rest but spread under applicator pressure. That approach could improve lesion coverage while reducing contact with uninvolved skin.

Film formation

A thin film-forming system could preserve cantharidin at the lesion and reduce accidental transfer to clothing, caregivers, or adjacent skin. Suitable polymers may include cellulose derivatives, polyvinylpyrrolidone derivatives, acrylate polymers, or other dermatologically acceptable film formers.

Film formation creates a tradeoff. Strong adhesion may improve dose retention but make wash-off more difficult and increase irritation. A commercially attractive product would need a predictable film that remains localized, is removed easily after the prescribed exposure period, and does not alter the blistering response.

Emollients and tolerability

An emollient can reduce the harsh sensory profile of volatile solvents and support spreadability. It may also change the rate at which cantharidin partitions into the stratum corneum. That effect must be controlled because excessive penetration into surrounding skin could increase pain, blistering, and post-inflammatory changes.

Excipient selection should therefore focus on localized delivery rather than maximal penetration. The target is lesion-specific exposure, not systemic absorption or broad skin permeation.

What formulation patents protect YCANTH?

YCANTH’s patent position is likely to derive from several layers rather than from the active ingredient alone:

Patent layer	Commercial purpose	Main workaround risk
Cantharidin composition	Protects defined concentrations and excipient combinations	Alternative concentration or solvent system
Topical treatment method	Protects treatment of molluscum contagiosum and related lesions	Different dosing interval, population, or treatment protocol
Applicator and package	Protects controlled application and single-use handling	Multidose tube, pump, swab, or alternative applicator
Manufacturing process	Protects dissolution, mixing, filling, and stability controls	Different order of addition or manufacturing parameters
Film-forming or viscosity system	Protects residence time and lesion localization	Different polymer, concentration, or solvent balance
Pediatric-use and exposure protocol	Supports product-specific use conditions	Alternative wash-off timing or home-use product

Cantharidin itself is an old compound and is not the principal source of durable exclusivity. The defensible value is more likely to reside in the specific formulation, delivery system, treatment protocol, and manufacturing controls.

The commercial implication is significant: a competing company may avoid a composition claim while preserving the same pharmacologic concept through a different solvent, polymer, package, or concentration. Freedom-to-operate analysis must therefore examine claim scope across formulation and method patents, not only patents that expressly recite YCANTH.

What is the FDA regulatory and Orange Book status of YCANTH?

The FDA approved YCANTH in July 2023 under the 505(b)(2) pathway for topical treatment of molluscum contagiosum in adults and pediatric patients aged 2 years and older (FDA, 2023b).

YCANTH is a prescription product with an FDA-approved label and a defined dosage form, strength, route, and applicator presentation. Its regulatory exclusivity is separate from patent protection. The approval created the regulatory reference product for future abbreviated or 505(b)(2) applicants.

For a competing product, the likely pathways are:

Pathway	Likely use
ANDA	A product demonstrating sameness to the reference product in active ingredient, dosage form, strength, route, and relevant pharmaceutical characteristics
505(b)(2) NDA	A materially different cantharidin formulation, concentration, delivery system, or use supported by new clinical or bridging data
Full NDA	A product with a sufficiently distinct clinical or pharmacologic profile
Compounded preparation	Patient-specific or limited pharmacy compounding, subject to federal and state requirements and restrictions on copying approved products

The Orange Book should be treated as the controlling source for listed patents, exclusivity, and the timing of any Paragraph IV certification. A patent listed for a formulation or method of use can delay approval of an ANDA following a Paragraph IV notice and timely patent litigation. A 30-month stay may apply under the Hatch-Waxman framework, subject to statutory conditions and litigation developments (FDA, 2024).

YCANTH’s regulatory advantage is that the formulation, labeling, and application process are already clinically validated. Its regulatory vulnerability is that a follow-on applicant may target the same active ingredient through a different formulation and pursue a 505(b)(2) strategy.

When does YCANTH lose exclusivity?

YCANTH’s exclusivity has several components:

1. FDA approval-related exclusivity.
2. Any pediatric exclusivity awarded under the Pediatric Research Equity Act framework.
3. Orange Book-listed patent protection.
4. Trade-secret protection for manufacturing and formulation controls.
5. Commercial protection created by the applicator, distribution model, and prescriber familiarity.

FDA approval in July 2023 does not by itself establish the end date for all exclusivity. The applicable end dates depend on the specific statutory exclusivity designation and the patents listed for the reference product.

Patent expiration dates also differ by family and by patent-term adjustment or terminal disclaimer. Formulation and method-of-use patents may expire later than basic composition claims. The highest-value claims are those that cover the concentration, excipient ratio, applicator, and treatment protocol together because they are harder to design around than a single broad use claim.

What commercial opportunities exist for YCANTH excipients?

Lower-irritation pediatric formulation

A next-generation formulation could target less stinging, reduced odor, and lower off-lesion spread. This is commercially attractive because molluscum contagiosum is concentrated in pediatric and family-care settings, where caregiver acceptance strongly affects treatment completion.

A lower-irritation product would need to preserve the expected blistering mechanism. Removing or materially reducing the local reaction could weaken clinical efficacy.

Longer shelf life and simpler distribution

Improved solvent and package compatibility could support longer shelf life, less leakage, and reduced shipping restrictions. These improvements may reduce cost in dermatology practices and specialty distribution.

Single-use packaging also creates opportunities for lower-cost materials, automated filling, tamper evidence, and improved applicator ergonomics. Packaging changes can be commercially important even when the formulation remains substantially unchanged.

Larger lesion-area coverage

YCANTH is administered by trained healthcare professionals. A product that enables more efficient treatment of numerous lesions could increase office throughput. Potential approaches include:

• A metered-dose applicator.
• A controlled-width brush tip.
• A unit-dose pen.
• A formulation with improved wetting and less runoff.
• A package that permits rapid treatment of multiple lesions without cross-contamination.

The key barrier is dose control. Increasing the treated area without increasing unintended exposure would require validated delivery mechanics and clinical bridging.

Home-use or caregiver-assisted products

A home-use cantharidin product could expand the addressable market by reducing office visits. The regulatory and safety burden would be high because cantharidin is a vesicant and accidental application to eyes, mucosal tissue, or uninvolved skin can cause injury.

The most credible near-term opportunity is not unrestricted home use. It is a controlled product for caregiver-assisted application after professional diagnosis and training, potentially with a low-volume applicator and physical dose limiter.

New dermatology indications

Cantharidin has been used historically for warts, but YCANTH’s approved indication is molluscum contagiosum. A company could pursue new indications through a separate clinical and regulatory program. Warts represent a larger potential treatment population but also a more crowded competitive field, including salicylic acid, cryotherapy, immunomodulators, and procedural treatments.

A formulation optimized for thicker keratinized lesions may need different solvent penetration, viscosity, exposure time, or concentration. That would create a new formulation and method-of-use patent opportunity.

Which companies are challenging YCANTH?

The competitive field includes four groups:

Competitor group	Examples of competitive approach	Risk level
Generic or 505(b)(2) developers	Cantharidin topical solution with alternative excipients or packaging	High after patent and exclusivity barriers decline
Compounding pharmacies	Patient-specific cantharidin preparations	Moderate, subject to regulatory limits and quality variation
Established dermatology companies	New prescription vesicants or lesion-directed products	Moderate
Existing standard treatments	Curettage, cryotherapy, keratolytics, and observation	High for price-sensitive or low-severity cases

A generic YCANTH-like product would compete primarily on price and payer access. A 505(b)(2) product could compete on reduced pain, fewer visits, larger coverage area, improved storage, or a more convenient applicator.

What generic entry risks exist for YCANTH?

The most plausible generic-entry scenarios are:

Scenario 1: Same or substantially similar topical solution

An ANDA applicant would seek to match the reference product’s active ingredient, strength, dosage form, route, and pharmaceutical characteristics. The principal barriers would be Orange Book patents, product-specific bioequivalence requirements, and the complexity of demonstrating comparable local performance.

Topical products can present bioequivalence challenges because clinical effect depends on local application, evaporation, lesion coverage, and residence time. A conventional plasma pharmacokinetic study may not adequately establish equivalence.

Scenario 2: Alternative excipient system

A 505(b)(2) applicant could use a different solvent, polymer, or applicator and rely partly on YCANTH’s existing safety and efficacy findings. The applicant might claim advantages such as lower irritation or improved stability.

This is the most important formulation risk because it avoids direct replication while preserving the same active ingredient and treatment concept.

Scenario 3: Compounded substitution

Compounded cantharidin may be used where commercially available product is inaccessible or unaffordable. However, compounded products may vary in concentration, sterility controls, packaging, labeling, and application consistency. The FDA has warned that compounded drugs do not undergo the same premarket review for safety, efficacy, and quality as approved products (FDA, 2023c).

How strong is the YCANTH patent estate?

The estate is strongest where claims combine:

• 0.7% cantharidin or a narrow concentration range.
• A defined solvent and polymer system.
• Single-use delivery.
• A specified lesion-treatment protocol.
• Controlled exposure and wash-off timing.
• Manufacturing parameters that prevent crystallization or concentration drift.

The estate is weaker against a product using a different solvent blend, a different thickener, a different package, and a clinically supported alternative dosing schedule. Because cantharidin is an established molecule, competitors have a clear incentive to pursue formulation and delivery workarounds.

Trade secrets may provide meaningful protection for manufacturing, but they do not prevent independent development. The most durable commercial strategy is to combine patent claims with device control, supply reliability, prescriber adoption, and clinical data supporting tolerability.

How does YCANTH compare with compounded cantharidin?

Attribute	YCANTH	Compounded cantharidin
FDA status	FDA-approved	Not FDA-approved as a finished product
Strength control	Defined 0.7% product	May vary by pharmacy and formulation
Packaging	Validated single-use applicator	Often tube, vial, or other container
Labeling	Standardized indication and instructions	Pharmacy-specific
Clinical evidence	Pivotal clinical development program	Usually limited product-specific evidence
Manufacturing controls	Commercial CMC and release specifications	Depends on pharmacy and facility
Commercial model	Prescription distribution and office administration	Often lower-cost, variable-access alternative

YCANTH can defend its premium through standardized dosing, validated quality, regulated labeling, and reduced handling risk. Compounded products remain a pricing threat, particularly in practices with established cantharidin workflows.

What revenue exposure and market opportunities does YCANTH have?

Verrica Pharmaceuticals reported growing YCANTH commercial sales after the U.S. launch, with revenue dependent on prescription volume, payer coverage, specialty-distribution execution, and physician adoption (Verrica Pharmaceuticals, 2025).

The product’s revenue model has several favorable characteristics:

• Molluscum contagiosum is common in children.
• Treatment is performed in dermatology and pediatric offices.
• The regimen can require multiple applications.
• The applicator supports controlled unit consumption.
• The product can replace compounded preparations and procedural treatment.

The main constraints are office capacity, reimbursement for drug administration, parent and child acceptance of blistering, and the availability of low-cost alternatives such as observation or cryotherapy.

The highest-value commercial extensions are improved tolerability, fewer treatment visits, broader lesion-area coverage, and additional indications. A lower-cost equivalent would expand access but could reduce branded pricing and increase payer substitution.

Key Takeaways

• YCANTH’s value is based on the combination of cantharidin, excipient system, applicator, packaging, and office-use protocol.
• Solvent selection is the central formulation variable because it controls solubility, evaporation, odor, spread, and local exposure.
• Rheology and film formation can support better lesion localization and reduce contact with uninvolved skin.
• The strongest patent strategy combines composition, method-of-use, applicator, manufacturing, and treatment-protocol claims.
• The most credible follow-on threat is a 505(b)(2) product with a different excipient system or delivery device.
• Compounded cantharidin is a price and access competitor but lacks the standardized regulatory package of YCANTH.
• Home-use products and new indications offer the largest formulation-led expansion opportunities, with safety and clinical-bridging requirements as the main barriers.
• Product-level exclusivity must be evaluated separately from Orange Book patents and FDA regulatory exclusivity.

FAQs

Can YCANTH be reformulated with a water-based excipient system?

A water-based system would need to overcome cantharidin’s limited water solubility and demonstrate chemical stability, uniform dosing, acceptable drying behavior, and comparable clinical performance. A materially different formulation would likely require a 505(b)(2) regulatory strategy rather than simple substitution.

What packaging improvements could increase YCANTH’s commercial value?

Improved applicator dose control, leak resistance, tamper evidence, low-cost unit-dose packaging, and compatibility with automated filling could reduce waste and office-handling costs. Packaging changes must preserve dose accuracy and prevent accidental exposure.

Could a cantharidin foam compete with YCANTH?

A foam could improve spreadability over larger or irregular lesion fields, but foam collapse, active uniformity, flammability, dose measurement, and stability would create substantial development requirements. It would likely be a differentiated 505(b)(2) product.

Are excipient patents more valuable than cantharidin composition patents?

In commercial terms, yes, when they cover a narrow formulation that improves stability, tolerability, localization, or dosing. Cantharidin is an established active ingredient, so formulation and delivery claims are more relevant to differentiation and design-around analysis.

Could YCANTH be used for common warts under its existing approval?

No. The FDA approval covers molluscum contagiosum, not common warts. Use for warts would require clinical support and a separate regulatory basis, even though cantharidin has historical use in wart treatment.

References

1. U.S. Food and Drug Administration. (2023a). YCANTH (cantharidin) topical solution, 0.7%: Prescribing information.
2. U.S. Food and Drug Administration. (2023b). FDA approves first treatment for molluscum contagiosum.
3. U.S. Food and Drug Administration. (2023c). Compounding and the FDA: Questions and answers.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. Verrica Pharmaceuticals Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024.